Back to your search result

Description

"All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction. The ChIPAb+JMJD1C set includes the JMJD1C antibody, a Normal Rabbit IgG, and control primers which amplify a 110 bp region of ChIP Primers, human beta-globin. The JMJD1C and negative controls are supplied in a scalable ""per ChIP"" reaction size and can be used to functionally validate the precipitation of JMJD1C -associated chromatin., JMJD1C (jumonji domain-containing protein 1C) is also known as TRIP8 and mutations in this histone demethylase have been linked to certain forms of autism. JMJD1C is also thought to work in reactivating genes in embryonic stem cells, pancreatic islet and gastric cancer. JMJD1C has also been implicated as a gene expression regulator. JMJD1C with WHISTLE have recently been shown to also play a role in mouse testis development. JMJD1C has been identified as a nuclear-receptor coactivator and is a candidate gene for autism."